{"id":963543,"date":"2026-05-15T10:24:14","date_gmt":"2026-05-15T14:24:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/"},"modified":"2026-05-15T10:24:14","modified_gmt":"2026-05-15T14:24:14","slug":"60-degrees-pharmaceuticals-announces-first-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/","title":{"rendered":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WASHINGTON, May  15, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Noq8YX96X06EtgKJluEA98SmKKyUxRemC52f5HUbriF73ZT1XV4W1gKlMmkQp7vRUekQaHuxtL4j8HPSCanHcFS1FTI8M-ZR5Wlnxz5YmLLjLzLKSrUmFROUIgGg2KwWb1i0YH_QrzGr1R_qduy_A==\" rel=\"nofollow\" target=\"_blank\"><u>60 Degrees Pharmaceuticals, Inc.\u00a0<\/u><\/a>(NASDAQ:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uVBM0JZkd4s6-tAK20jOHrUucbOC30sod5IuuHXFOHJMRQbqq9scmcjAtmlarTlhl9-0kDyvoBePvFlpxDj4Ey6ueGLFo4G-t1HND-2rM2RI1_t53_1-OadzJfNVOe-gtgr-WE7Jz0Pa251c0ojdgw==\" rel=\"nofollow\" target=\"_blank\"><u>SXTP<\/u><\/a>; SXTPW) (the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended\u00a0March 31, 2026.<\/p>\n<p>Financial Highlights for the Quarter Ended\u00a0March 31, 2026:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Net product revenues decreased approximately 1% from\u00a0$164 thousand\u00a0for the first quarter of 2025 to approximately\u00a0$162 thousand\u00a0for the first quarter of 2026.<\/li>\n<li style=\"margin-bottom:8pt\">The Company achieved a gross profit of approximately\u00a0$76 thousand\u00a0in the first quarter of 2026, compared with a gross profit of approximately $90 thousand\u00a0in the first quarter of 2025.<\/li>\n<li style=\"margin-bottom:8pt\">Operating expenses were approximately\u00a0$2.17 million\u00a0in the first quarter of 2026, compared with approximately\u00a0$2.09 million\u00a0in the first quarter of 2025.<\/li>\n<li style=\"margin-bottom:8pt\">Net loss attributable to common shareholders in the first quarter of 2026 was approximately $2.21 million, or a net loss of $1.28 per share, compared with a net loss of approximately $2.00 million, or a net loss of $6.25 per share, in the first quarter of 2025.\n<\/li>\n<\/ul>\n<p>\n        <strong>About\u00a060 Degrees Pharmaceuticals, Inc.<\/strong><br \/>\n        <br \/>60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved\u00a0U.S. Food and Drug Administration\u00a0approval of its lead product, ARAKODA<sup>\u00ae<\/sup>\u00a0(tafenoquine) in 2018. ARAKODA is commercially available in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0also collaborates with prominent research and academic organizations in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0is headquartered in\u00a0Washington, D.C., with a subsidiary in\u00a0Australia. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qXXCMsjGpboq6ML0NH2MhvpuOSeurroxQhPMZ5IQoHNYa0xiuo8WmT31hYXLq-Z2k8UV8-9Lx152F9lb7sDdQfxXphnwIauvAoqGpnYR1lyi0iUIf7a3iKtLGlF7yX8E\" rel=\"nofollow\" target=\"_blank\"><u>www.60degreespharma.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release may contain \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Forward\u2010looking statements reflect the current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward\u2010looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for\u00a0tafenoquine\u00a0(ARAKODA<sup>\u00ae<\/sup> or other regimen) or Australian Chestnut Extract and\/or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.\u00a0More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d), including the information contained in our Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0March 30, 2026, and our subsequent\u00a0SEC\u00a0filings. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at\u00a0www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company\u2019s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>Media Contact:<br \/>Sheila A. Burke<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9hRJBYTkixvJZSojQ9R_yexsXIHRmI55BMdOYYt0z0j27om4D6Ib-a0T9ww3JK8wXW4RYGClv83dQsp6dKZehEQ5GEgNkxQg_At4VDAOsqjwjfdrRpiw601ae0UP1xLDL0R9Sfd6cwupx3Ry5XmoazHAFLDMwjrlaf9Xs4kG1T8=\" rel=\"nofollow\" target=\"_blank\"><u>SheilaBurke-consultant@60degreespharma.com<\/u><\/a><br \/>(484) 667-6330<\/p>\n<p>Investor Contact:<br \/>Patrick Gaynes<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p2WBE1DnPu4_jdXc4soTMMeZmf3JNBGuJUNu3-pen8ur9ezRZa0w75Y0nB9SC4z1-4NlPmdsOYe6iEnLjjFH5hhg8d_8g6fUzgZQlk6m1qdg0DSU8wfxzdyYQSkXGVVsEC6r8y5AEpRhTxb0Wd3q3g==\" rel=\"nofollow\" target=\"_blank\"><u>patrickgaynes@60degreespharma.com<\/u><\/a><br \/>(310) 989-5666<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmZhMjYyOGYtMTU4Yy00Y2M2LWE3OGItNDY4ODFlMzg2YWUxLTExOTM5MDctMjAyNi0wNS0xNS1lbg==\/tiny\/Sixty-Degrees-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ:\u00a0SXTP; SXTPW) (the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended\u00a0March 31, 2026. Financial Highlights for the Quarter Ended\u00a0March 31, 2026: Net product revenues decreased approximately 1% from\u00a0$164 thousand\u00a0for the first quarter of 2025 to approximately\u00a0$162 thousand\u00a0for the first quarter of 2026. The Company achieved a gross profit of approximately\u00a0$76 thousand\u00a0in the first quarter of 2026, compared with a gross profit of approximately $90 thousand\u00a0in the first quarter of 2025. Operating expenses were approximately\u00a0$2.17 million\u00a0in the first quarter of 2026, compared with approximately\u00a0$2.09 million\u00a0in the first quarter of 2025. Net loss attributable &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;60 Degrees Pharmaceuticals Announces First Quarter 2026 Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963543","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ:\u00a0SXTP; SXTPW) (the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended\u00a0March 31, 2026. Financial Highlights for the Quarter Ended\u00a0March 31, 2026: Net product revenues decreased approximately 1% from\u00a0$164 thousand\u00a0for the first quarter of 2025 to approximately\u00a0$162 thousand\u00a0for the first quarter of 2026. The Company achieved a gross profit of approximately\u00a0$76 thousand\u00a0in the first quarter of 2026, compared with a gross profit of approximately $90 thousand\u00a0in the first quarter of 2025. Operating expenses were approximately\u00a0$2.17 million\u00a0in the first quarter of 2026, compared with approximately\u00a0$2.09 million\u00a0in the first quarter of 2025. Net loss attributable &hellip; Continue reading &quot;60 Degrees Pharmaceuticals Announces First Quarter 2026 Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T14:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results\",\"datePublished\":\"2026-05-15T14:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/\"},\"wordCount\":762,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/\",\"name\":\"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\",\"datePublished\":\"2026-05-15T14:24:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/","og_locale":"en_US","og_type":"article","og_title":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk","og_description":"WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) &#8212; 60 Degrees Pharmaceuticals, Inc.\u00a0(NASDAQ:\u00a0SXTP; SXTPW) (the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended\u00a0March 31, 2026. Financial Highlights for the Quarter Ended\u00a0March 31, 2026: Net product revenues decreased approximately 1% from\u00a0$164 thousand\u00a0for the first quarter of 2025 to approximately\u00a0$162 thousand\u00a0for the first quarter of 2026. The Company achieved a gross profit of approximately\u00a0$76 thousand\u00a0in the first quarter of 2026, compared with a gross profit of approximately $90 thousand\u00a0in the first quarter of 2025. Operating expenses were approximately\u00a0$2.17 million\u00a0in the first quarter of 2026, compared with approximately\u00a0$2.09 million\u00a0in the first quarter of 2025. Net loss attributable &hellip; Continue reading \"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T14:24:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results","datePublished":"2026-05-15T14:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/"},"wordCount":762,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/","name":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=","datePublished":"2026-05-15T14:24:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTIzMiM3NjA0OTEyIzIxODIzMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-announces-first-quarter-2026-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"60 Degrees Pharmaceuticals Announces First Quarter 2026 Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963543"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963543\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}